Search

Author/Creator Riser, Emily

1. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Issue 7 (July 2022)

Authors:
Foley, John F; Defer, Gilles; Ryerson, Lana Zhovtis; Cohen, Jeffrey A; Arnold, Douglas L; Butzkueven, Helmut; Cutter, Gary; Giovannoni, Gavin; Killestein, Joep; Wiendl, Heinz; Smirnakis, Karen; Xiao, Shan; Kong, George; Kuhelj, Robert; Campbell, Nolan; van der Walt, Anneke; Dwyer, Christopher; Bu...
Journal:
Lancet neurology
Issue:
Volume 21:Issue 7(2022)
Page Start:
608
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis. Issue 2 (April 2020)

Authors:
Buckle, Guy; Bandari, Daniel; Greenstein, Jeffrey; Gudesblatt, Mark; Khatri, Bhupendra; Kita, Mariko; Repovic, Pavle; Riser, Emily; Weinstock-Guttman, Bianca; Thrower, Ben; Loring, Sherrill; Riester, Katherine; Everage, Nick; Prada, Claudia; Koulinska, Irene; Mann, Monica
Journal:
Multiple sclerosis journal, experimental, translational and clinical
Issue:
Volume 6:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗